Pharmacogenomic analysis services of participants enrolled in the star-b randomized clinical trial of semaglutide for alcohol use disorder
Active Purchase Order Awarded Last action
- Contract number
- 75N98026P01685
- Awardee
-
Novogene Corporation Inc. UEI KM6KF2YEWNN6
- Awarding agency
-
Office of Logisitics and Acquisition Operations
National Institutes of Health, Department of Health and Human Services
- Obligated
- $25,000
Award facts
- Opportunity
-
- Pharmacogenomic Analysis of Participants Enrolled in the STAR-B Randomized Clinical Trial of Semaglutide for Alcohol Use Disorder Special Notice · NOIPCANIDA09054 · Posted Sep 8, 2026
- Contract value 100% obligated
- $24,999.99 Current and potential, with all options
- Completion date 10% complete
- Current and potential, with all options
- Funding agency
- National Institute on Drug Abuse National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Sacramento, CA 95817, USA
Award details come from SAM.gov/FPDS.
About this award
The National Institute on Drug Abuse awarded a purchase order to Novogene Corporation Inc., a minority-owned small business, for $24,999.99 on September 17, 2026, for pharmacogenomic analysis services supporting the STAR-B randomized clinical trial of semaglutide for alcohol use disorder treatment.
Work is performed in Sacramento, California. The contractor will conduct biospecimen receipt and processing, DNA extraction, quality control assessment, genome-wide genotyping and/or sequencing, standard bioinformatics processing, and delivery of raw and processed genomic data with documentation. The award was sole-sourced based on continuity with Novogene's ongoing sequencing services for the parallel STAR-T study at Oklahoma State University, preserving research design consistency for cross-study comparison. The period of performance is 12 months, with completion expected by September 16, 2027. All genomic data remains NIH property and is restricted to NIDA Intramural Research Program clinical teams; samples and data are de-identified prior to contractor receipt.
Quick answers
Who was awarded contract 75N98026P01685?
75N98026P01685 was awarded to Novogene Corporation Inc. by Office of Logisitics and Acquisition Operations (National Institutes of Health) on September 17, 2026.
How much is contract 75N98026P01685 worth?
The government has obligated $25,000 on 75N98026P01685.
Which agency awarded contract 75N98026P01685?
Office of Logisitics and Acquisition Operations (National Institutes of Health) awarded 75N98026P01685, with funding from National Institute on Drug Abuse (National Institutes of Health).
Was contract 75N98026P01685 competed?
The extent of competition for 75N98026P01685 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award